Depression of complement activity in three strains of mice after tumor transfer

Drake, Walter P.; LeGendre, Stephen M.; Mardiney, Michael R.

doi:10.1002/ijc.2910110323

Cited by 6 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…." The role of complement as a limiting reagent was further demonstrated by Old et al (1967), Negroni and Hunter (1973), Drake et al (1973), Koene et al (1973), and Harveit and Cater (1971). In each of the model systems studied, the addition of a complement source resulted in tumor-cell kill or graft rejection.…”

Section: Complement In Tumor-bearing Animalsmentioning

confidence: 85%

Complement in Cancer

Kassel

HardyJr.

Day

1977

Biological Amplification Systems in Immunology

View full text Add to dashboard Cite

Section: Complement In Tumor-bearing Animalsmentioning

confidence: 85%

Complement in Cancer

Kassel

HardyJr.

Day

1977

Biological Amplification Systems in Immunology

View full text Add to dashboard Cite

“…Thus, complement deficiency (whether relative or absolute) can be viewed as another mechanism whereby tumor cells escape the consequences of their antigenicity. In this regard, reduced levels of complement have been found in the serum of tumor-bearing mice (27,28). This provides the most likely explanation for our observation that such sera lack antileukemic activity in AKR mice.…”

Section: Discussionmentioning

confidence: 53%

Serum-Mediated Leukemia Cell Destruction in Akr Mice

Kassel

Old

Carswell

et al. 1973

The Journal of Experimental Medicine

View full text Add to dashboard Cite

AKR mice with spontaneous leukemia were infused with normal serum from a variety of species. Leukemia cell destruction was produced by serum from strains of mice possessing the full spectrum of complement components, but not by serum from strains with a genetically determined deficiency of C5. Serum from guinea pigs, horses, and humans also causes destruction of leukemia cells. The antileukemic factor in normal serum was heat labile (56°C for 35 min) and could be inactivated by cobra venom factor (CVF). Tests of individual complement factors from guinea pig serum and from human serum suggest that C5 is the antileukemic complement component in normal serum. Evidence was obtained that complement also plays a role in the antileukemic effect of interferon and endotoxin.

show abstract

“…With the exception of the recent reports by Drake et al [18,19], studies on the changes of C levels in tumor-bearing ani mals have not been carried out in syngeneic hosts [19,20], Nor has it been the general practice to assay sequential bleedings from the same animal. Yet virtually all investiga tors have reported lowered hemolytic activ ity levels of the classical C system.…”

Section: Discussionmentioning

confidence: 99%

Serum Complement Changes in W/Fu Rats Inoculated with Syngeneic (C58NT) D Lymphoma Cells

Lew¹,

Yukiyama²,

Osler³

1977

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Weanling W/Fu rats were inoculated intraperitoneally with 1 × 10⁶ to 1 × 10⁷ (C58NT)D Gross virus-induced lymphoma cells. Sera obtained 7 days later showed moderate to marked depressions of overall hemolytic activity, C1, C3 and properdin. These changes were not observed in uninjected W/Fu rats or in animals inoculated with syngeneic normal spleen cells. In the latter group and in the tumor-bearing animals, factor B levels were also depressed. Evidence of complement utilization was also observed in the ascitic fluids of the tumor-bearing W/Fu rats.

show abstract

Depression of complement activity in three strains of mice after tumor transfer

Cited by 6 publications

References 13 publications

Complement in Cancer

Complement in Cancer

Serum-Mediated Leukemia Cell Destruction in Akr Mice

Serum Complement Changes in W/Fu Rats Inoculated with Syngeneic (C58NT) D Lymphoma Cells

Contact Info

Product

Resources

About